Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Jan;38(1):151–154. doi: 10.1128/aac.38.1.151

Pharmacokinetics of meropenem in patients with intra-abdominal infections.

A Bedikian 1, M P Okamoto 1, R K Nakahiro 1, J Farino 1, P N Heseltine 1, M D Appleman 1, A E Yellin 1, T V Berne 1, M A Gill 1
PMCID: PMC284414  PMID: 8141572

Abstract

Noncompartmental and compartmental analyses of meropenem disposition in patients receiving 1-g intravenous intermittent infusions every 8 h were performed. Twelve patients (one woman and 11 men) participated in the meropenem pharmacokinetic analysis. Operative findings included perforated appendicitis (five patients), gangrenous appendicitis (five patients), peri-appendical abscess (one patient), and gunshot wound to the abdomen (one patient). The most common associated adverse drug reactions to meropenem were diarrhea and increased liver enzymes. The estimated noncompartmental pharmacokinetic parameters, mean +/- standard deviation, are as follows: maximum drug concentration in plasma, 47.58 +/- 17.59 micrograms/ml; half-life, 1.04 +/- 0.19 h; elimination rate constant, 0.68 +/- 0.12 h-1; area under the concentration-time curve from 0 h to infinity, 57.5 +/- 20.12 micrograms x ml/h; total plasma clearance, 315.40 +/- 71.94 ml/min; renal clearance, 136.7 +/- 89.20 ml/min; volume of distribution at steady state, 26.68 +/- 6.88 liters; and mean residence time, 1.47 +/- 0.28 h. The two-compartment model best described meropenem disposition in our patients. Our findings differed from estimates for healthy volunteers possibly because of the physiologic changes as a result of surgery. Our findings suggest that meropenem (1,000 mg) administered intravenously every 8 h provides adequate concentrations for most intra-abdominal infections.

Full text

PDF
151

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer L. A., Gibaldi M. Computation of model-independent pharmacokinetic parameters during multiple dosing. J Pharm Sci. 1983 Aug;72(8):978–979. doi: 10.1002/jps.2600720843. [DOI] [PubMed] [Google Scholar]
  2. Bax R. P., Bastain W., Featherstone A., Wilkinson D. M., Hutchison M., Haworth S. J. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):311–320. doi: 10.1093/jac/24.suppl_a.311. [DOI] [PubMed] [Google Scholar]
  3. Burman L. A., Nilsson-Ehle I., Hutchison M., Haworth S. J., Norrby S. R. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J Antimicrob Chemother. 1991 Feb;27(2):219–224. doi: 10.1093/jac/27.2.219. [DOI] [PubMed] [Google Scholar]
  4. Chimata M., Nagase M., Suzuki Y., Shimomura M., Kakuta S. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother. 1993 Feb;37(2):229–233. doi: 10.1128/aac.37.2.229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Christensson B. A., Nilsson-Ehle I., Hutchison M., Haworth S. J., Oqvist B., Norrby S. R. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992 Jul;36(7):1532–1537. doi: 10.1128/aac.36.7.1532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  7. Jelliffe R. W., Schumitzky A. Modeling, adaptive control, and optimal drug therapy. Med Prog Technol. 1990 May;16(1-2):95–110. [PubMed] [Google Scholar]
  8. Jorgensen J. H., Maher L. A., Howell A. W. Activity of a new carbapenem antibiotic, meropenem, against Haemophilus influenzae strains with beta-lactamase- and non-enzyme-mediated resistance to ampicillin. Antimicrob Agents Chemother. 1991 Mar;35(3):600–602. doi: 10.1128/aac.35.3.600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Leroy A., Fillastre J. P., Etienne I., Borsa-Lebás F., Humbert G. Pharmacokinetics of meropenem in subjects with renal insufficiency. Eur J Clin Pharmacol. 1992;42(5):535–538. doi: 10.1007/BF00314864. [DOI] [PubMed] [Google Scholar]
  10. Ljungberg B., Nilsson-Ehle I. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men. Antimicrob Agents Chemother. 1992 Jul;36(7):1437–1440. doi: 10.1128/aac.36.7.1437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Moellering R. C., Jr, Eliopoulos G. M., Sentochnik D. E. The carbapenems: new broad spectrum beta-lactam antibiotics. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):1–7. doi: 10.1093/jac/24.suppl_a.1. [DOI] [PubMed] [Google Scholar]
  12. Mouton J. W., Michel M. F. Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion. J Antimicrob Chemother. 1991 Dec;28(6):911–918. doi: 10.1093/jac/28.6.911. [DOI] [PubMed] [Google Scholar]
  13. Nilsson-Ehle I., Hutchison M., Haworth S. J., Norrby S. R. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Eur J Clin Microbiol Infect Dis. 1991 Feb;10(2):85–88. doi: 10.1007/BF01964413. [DOI] [PubMed] [Google Scholar]
  14. Nord C. E., Lindmark A., Persson I. Susceptibility of anaerobic bacteria to meropenem. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):113–117. doi: 10.1093/jac/24.suppl_a.113. [DOI] [PubMed] [Google Scholar]
  15. Reed R. L., 2nd, Wu A. H., Miller-Crotchett P., Crotchett J., Fischer R. P. Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. J Trauma. 1989 Nov;29(11):1462–1470. doi: 10.1097/00005373-198911000-00002. [DOI] [PubMed] [Google Scholar]
  16. Rocci M. L., Jr, Jusko W. J. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed. 1983 Jun;16(3):203–216. doi: 10.1016/0010-468x(83)90082-x. [DOI] [PubMed] [Google Scholar]
  17. Wise R., Logan M., Cooper M., Ashby J. P., Andrews J. M. Meropenem pharmacokinetics and penetration into an inflammatory exudate. Antimicrob Agents Chemother. 1990 Aug;34(8):1515–1517. doi: 10.1128/aac.34.8.1515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978 Apr;6(2):165–175. doi: 10.1007/BF01117450. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES